Sarepta Therapeutics' digital transformation strategy centers on accelerating the development and delivery of precision genetic medicines. The company is actively investing in advanced manufacturing systems, standardizing clinical trial data workflows, and developing platform technologies to streamline drug development. This approach allows Sarepta Therapeutics to bring innovative treatments to patients with rare diseases more rapidly. They prioritize creating robust digital infrastructures that support complex R&D pipelines, manufacturing scale-up, and global regulatory submissions.
This transformation creates critical dependencies on integrated data systems, robust regulatory compliance platforms, and high-fidelity manufacturing processes. Challenges arise from managing vast amounts of scientific data, ensuring data integrity across clinical trials, and adapting to dynamic regulatory environments. This page analyzes Sarepta Therapeutics' key digital transformation initiatives, the operational challenges they face, and where sellers can find opportunities.
Sarepta Therapeutics Snapshot
Headquarters: Cambridge, USA
Number of employees: 835
Public or private: Public
Business model: Other (Biopharmaceutical, precision genetic medicine)
Sarepta Therapeutics ICP and Buying Roles
- Biopharmaceutical companies developing complex genetic therapies.
- Life sciences organizations managing extensive clinical trial portfolios.
Who drives buying decisions
- Chief Technology Officer → Oversees the adoption of new digital platforms and infrastructure across the organization.
- Head of Research & Development → Drives the implementation of systems that accelerate drug discovery and clinical development processes.
- VP of Manufacturing Operations → Manages the digitalization of production lines and supply chain systems.
- Head of Clinical Operations → Directs the standardization and optimization of clinical data collection and analysis tools.
- Chief Regulatory Officer → Ensures compliance with global health authority requirements through specialized regulatory platforms.
Key Digital Transformation Initiatives at Sarepta Therapeutics (At a Glance)
- Expanding Gene Therapy Manufacturing Capacity: Building internal capabilities and external partnerships for large-scale gene therapy production.
- Standardizing Clinical Data Management: Integrating data from diverse clinical sources for faster review and analysis.
- Developing Platform Technology for Drug Development: Utilizing a standardized viral vector for multiple investigational gene therapies to streamline regulatory processes.
- Prioritizing R&D Pipeline with siRNA Focus: Optimizing resource allocation for high-impact genetic medicine programs.
- Managing Global Web Content: Implementing a unified digital ecosystem for multiple international websites with multilingual support.
Where Sarepta Therapeutics’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Manufacturing Execution Systems | Expanding Gene Therapy Manufacturing Capacity: real-time production data does not propagate to quality control systems. | VP of Manufacturing Operations | Standardize data flow between manufacturing lines and quality assurance. |
| Expanding Gene Therapy Manufacturing Capacity: batch record generation requires manual data entry. | Director of Process Development | Automate data capture for electronic batch records without human input. | |
| Expanding Gene Therapy Manufacturing Capacity: material traceability breaks when integrating partner supply data. | Head of Supply Chain | Enforce consistent material tracking across internal and external facilities. | |
| Clinical Data Management Platforms | Standardizing Clinical Data Management: raw data ingestion fails to match standardized formats. | Head of Clinical Data Management | Validate incoming clinical data against predefined study protocols. |
| Standardizing Clinical Data Management: protocol amendments create mismatch in existing case report forms. | Director of Clinical Operations | Route protocol changes for automated update of trial documentation. | |
| Standardizing Clinical Data Management: diverse data sources create incomplete patient safety profiles. | Head of Pharmacovigilance, Clinical Research | Detect missing data points in integrated safety data streams. | |
| R&D and Regulatory Information Systems | Developing Platform Technology for Drug Development: research data fails to link to regulatory submission documents. | Head of Regulatory Affairs | Enforce data connectivity between R&D outputs and eCTD publishing systems. |
| Developing Platform Technology for Drug Development: platform changes result in missing historical study data. | VP of R&D Operations | Prevent data loss during revisions to gene therapy platform specifications. | |
| Prioritizing R&D Pipeline with siRNA Focus: project progress reporting breaks due to inconsistent data inputs. | Director of R&D Portfolio Management | Standardize project metrics across diverse siRNA programs. | |
| Digital Asset Management Systems | Managing Global Web Content: localized website content does not synchronize across regional platforms. | Head of Digital Marketing | Enforce consistent content updates across all global web properties. |
| Managing Global Web Content: multilingual content approval routing blocks timely publication. | Director of Global Communications | Route content for faster linguistic and compliance review. |
Identify when companies like Sarepta Therapeutics are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Sarepta Therapeutics’s digital transformation unique
Sarepta Therapeutics' digital transformation uniquely prioritizes the integration of complex genetic science with robust operational systems. Their approach heavily depends on creating scalable manufacturing capacity and highly standardized clinical data workflows to rapidly advance rare disease therapies. This transformation involves intricate data management challenges due to the specificity and sensitivity of genetic medicine and the urgency of patient needs. Their journey includes navigating dynamic regulatory landscapes, which makes data integrity and system flexibility critical for maintaining compliance.
Sarepta Therapeutics’s Digital Transformation: Operational Breakdown
DT Initiative 1: Expanding Gene Therapy Manufacturing Capacity
What the company is doing
Sarepta Therapeutics is building its gene therapy manufacturing capacity through a hybrid model, combining internal expertise with strategic external partnerships. This involves developing advanced process, analytical, and quality control capabilities internally while leveraging contract development and manufacturing organizations. They focus on establishing dedicated facilities and personnel for large-scale production of complex genetic medicines.
Who owns this
- VP of Manufacturing Operations
- Head of Technical Operations
- Director of Supply Chain
- Head of Quality Control
Where It Fails
- Raw material inventory data does not propagate between partner sites and internal ERP systems.
- Production line equipment failures create inconsistent batch records.
- Quality control data from external labs requires manual input into internal QMS.
- Deviation reporting workflow breaks when integrating data from multiple manufacturing sites.
- Product release processes delay due to unstandardized analytical methods from different partners.
Talk track
Noticed Sarepta Therapeutics is expanding its gene therapy manufacturing capacity. Been looking at how some biopharma teams standardize material tracking across internal and external facilities instead of reconciling disparate systems, can share what’s working if useful.
DT Initiative 2: Standardizing Clinical Data Management and Analytics
What the company is doing
Sarepta Therapeutics is standardizing clinical trial designs and data collection strategies through partnerships with technology providers. They aim to accelerate data review for rare disease clinical trials by integrating various data sources into a centralized analytics platform. This involves creating reusable libraries for case report forms and implementing agile data management processes.
Who owns this
- Head of Clinical Operations
- Director of Clinical Data Management
- VP of Biometrics and Data Science
- Head of Medical Affairs
Where It Fails
- Case report form data breaks when new study protocols introduce unmapped fields.
- Patient-reported outcome data fails to integrate consistently from diverse mobile applications.
- Clinical analytics dashboards display incomplete information due to disconnected lab data feeds.
- Safety event reporting processes block regulatory submissions due to unvalidated source data.
- Study startup timelines extend when reusable data components do not apply across new trials.
Talk track
Saw Sarepta Therapeutics is standardizing clinical data management. Been looking at how some clinical teams validate incoming data against study protocols instead of correcting errors later, happy to share what we’re seeing.
DT Initiative 3: Platform Technology Development and Regulatory Integration
What the company is doing
Sarepta Therapeutics focused on developing and leveraging platform technologies, specifically a viral vector (rAAVrh74), to streamline drug development and regulatory reviews for multiple gene therapies. This involved submitting for and receiving an FDA Platform Technology Designation to use pooled evidence for subsequent drug applications.
Who owns this
- Chief Scientific Officer
- Head of Regulatory Affairs
- VP of Research & Development
- Director of Portfolio Strategy
Where It Fails
- R&D data generated for one gene therapy platform does not propagate to new drug applications.
- Regulatory submission documents contain inconsistent technical specifications across platform-derived therapies.
- Adverse event data from early trials creates discrepancies in updated safety profiles for related platform products.
- Platform design changes result in missing historical rationale for regulatory audit trails.
- Cross-study data analysis blocks when comparing efficacy across different genetic medicine programs using the same vector.
Talk track
Looks like Sarepta Therapeutics worked to develop platform technologies for gene therapy. Been seeing how some R&D teams enforce data traceability from research to regulatory filings instead of manually consolidating, can share what’s working if useful.
DT Initiative 4: R&D Portfolio Management and Resource Optimization
What the company is doing
Sarepta Therapeutics undertook a strategic restructuring and pipeline reprioritization, focusing on high-impact programs, particularly the siRNA platform. This involves optimizing resource allocation, managing a diverse pipeline of genetic medicines, and making strategic investments in R&D to advance promising therapies.
Who owns this
- Chief Financial Officer
- VP of Portfolio Management
- Head of Research & Development
- Director of Corporate Strategy
Where It Fails
- Project funding allocations break when R&D milestones are not met.
- Resource scheduling for preclinical studies creates conflicts across prioritized siRNA programs.
- Pipeline progress reports contain incomplete data due to disconnected departmental tracking systems.
- Decision-making for pipeline advancement blocks when risk assessments lack standardized metrics.
- Investment prioritization shifts when financial models do not reflect real-time R&D expenditures.
Talk track
Seems like Sarepta Therapeutics is prioritizing its R&D pipeline. Been seeing how some biopharma leadership teams standardize project metrics across diverse programs instead of relying on varied departmental reports, happy to share what we’re seeing.
Who Should Target Sarepta Therapeutics Right Now
This account is relevant for:
- Manufacturing Execution System providers
- Clinical Data Management and Analytics platforms
- R&D and Regulatory Information System vendors
- AI-powered Data Governance platforms for Life Sciences
- Biopharma Supply Chain Optimization solutions
Not a fit for:
- Generalist IT staffing agencies
- Basic HR software providers
- Consumer-facing marketing automation tools
- Standard office productivity software
- Infrastructure-as-a-Service providers without specialized GxP compliance.
When Sarepta Therapeutics Is Worth Prioritizing
Prioritize if:
- You sell solutions that standardize data flow between complex manufacturing processes and quality systems.
- You sell clinical data validation tools that prevent data ingestion failures for rare disease trials.
- You sell regulatory information systems that enforce data traceability from R&D platforms to submission documents.
- You sell portfolio management platforms that standardize project metrics across diverse R&D programs.
- You sell digital asset management systems that enforce consistent multilingual content synchronization across global web properties.
Deprioritize if:
- Your solution does not address specific data integrity or workflow breakdown challenges in biopharmaceutical R&D or manufacturing.
- Your product is limited to basic functionality with no GxP compliance capabilities.
- Your offering is not built for complex multi-system environments prevalent in drug development.
Who Can Sell to Sarepta Therapeutics Right Now
Manufacturing Execution Systems (MES)
Rockwell Automation - This company provides industrial automation and information solutions, including MES software that controls and monitors manufacturing processes.
Why they are relevant: Production line equipment failures create inconsistent batch records, delaying product release. Rockwell Automation's MES can standardize data collection and enforce real-time process control, ensuring complete and accurate batch records for gene therapy manufacturing.
Siemens Digital Industries Software - This company offers a comprehensive portfolio of software for product lifecycle management, including MES and MOM (Manufacturing Operations Management) solutions for process industries.
Why they are relevant: Raw material inventory data does not propagate between partner sites and internal ERP systems. Siemens' MOM suite can integrate data from various sources, preventing data discrepancies and ensuring accurate material traceability across Sarepta's hybrid manufacturing network.
Clinical Data Management & Analytics Platforms
Medidata Solutions (an IQVIA company) - This company offers a unified platform for clinical development, including electronic data capture (EDC), clinical trial management systems (CTMS), and clinical analytics.
Why they are relevant: Clinical analytics dashboards display incomplete information due to disconnected lab data feeds. Medidata's platform can centralize and integrate diverse clinical data sources, providing a comprehensive view for faster and more accurate clinical insights.
eClinical Solutions - This company provides an end-to-end clinical data management platform, elluminate, which unifies data from various sources and offers centralized analytics.
Why they are relevant: Study startup timelines extend when reusable data components do not apply across new trials. eClinical Solutions' elluminate platform can standardize clinical data processes and facilitate the reuse of study components, accelerating trial initiation.
R&D and Regulatory Information Management Systems
Veeva Systems - This company offers cloud-based software for the life sciences industry, including solutions for clinical, regulatory, quality, and R&D content management.
Why they are relevant: Regulatory submission documents contain inconsistent technical specifications across platform-derived therapies. Veeva's RIM (Regulatory Information Management) suite can enforce consistent document management and data integrity, streamlining regulatory submissions for Sarepta's genetic medicine platforms.
IQVIA - This company provides advanced analytics, technology solutions, and clinical research services to the life sciences industry, including regulatory and safety solutions.
Why they are relevant: Adverse event data from early trials creates discrepancies in updated safety profiles for related platform products. IQVIA's safety and regulatory solutions can standardize the capture and integration of safety data, ensuring consistent and compliant reporting across the product lifecycle.
R&D Portfolio and Project Management Software
Planisware - This company provides enterprise project portfolio management (PPM) software designed for product development, R&D, and IT organizations.
Why they are relevant: Project funding allocations break when R&D milestones are not met across diverse siRNA programs. Planisware's PPM software can centralize project data and enforce milestone tracking, enabling accurate financial forecasting and resource management for Sarepta's pipeline.
Oracle Primavera - This company offers project portfolio management solutions that help organizations prioritize, plan, manage, and execute projects and programs.
Why they are relevant: Resource scheduling for preclinical studies creates conflicts across prioritized siRNA programs. Oracle Primavera can optimize resource allocation and visualize project dependencies, preventing bottlenecks in Sarepta's R&D efforts.
Final Take
Sarepta Therapeutics is scaling its gene therapy manufacturing and standardizing clinical data workflows to accelerate drug development for rare diseases. Breakdowns are visible in data synchronization between diverse manufacturing partners, inconsistent clinical data ingestion, and unstandardized regulatory information. This account is a strong fit for vendors who provide specialized solutions that enforce data integrity and workflow automation across complex biopharmaceutical R&D, manufacturing, and regulatory processes.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.